06:46 AM EDT, 09/12/2025 (MT Newswires) -- AbbVie ( ABBV ) has settled a lawsuit with manufacturers that filed abbreviated new drug applications with the US Food and Drug Administration for generic versions of the company's upadacitinib tablets, a regulatory filing showed Thursday.

AbbVie ( ABBV ) said that assuming the company is granted pediatric exclusivity, it does not expect any generic upadacitinib tablets in the United States before April 2037.

Upadacitinib, currently sold under the Rinvoq brand, is used to treat rheumatoid arthritis, psoriatic arthritis, eczema, and other conditions.